Allogene Therapeutics Management
Management criteria checks 2/4
Allogene Therapeutics' CEO is David Chang, appointed in Jun 2018, has a tenure of 5.92 years. total yearly compensation is $14.06M, comprised of 5.1% salary and 94.9% bonuses, including company stock and options. directly owns 3.06% of the company’s shares, worth $14.43M. The average tenure of the management team and the board of directors is 1.3 years and 6.1 years respectively.
Key information
David Chang
Chief executive officer
US$14.1m
Total compensation
| CEO salary percentage | 5.1% |
| CEO tenure | 5.9yrs |
| CEO ownership | 3.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Allogene: Leading The Allogeneic CAR-T Space, Again
Apr 01Allogene: Lifting Of The Clinical Hold Will Be A Major Binary
Jan 12We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Nov 05Ramifications Of Allogene's Clinical Hold: Possible Sector-Wide Implications
Oct 19Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
Oct 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$14m | US$724k | -US$327m |
| Sep 30 2023 | n/a | n/a | -US$333m |
| Jun 30 2023 | n/a | n/a | -US$355m |
| Mar 31 2023 | n/a | n/a | -US$351m |
| Dec 31 2022 | US$15m | US$724k | -US$340m |
| Sep 30 2022 | n/a | n/a | -US$313m |
| Jun 30 2022 | n/a | n/a | -US$308m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$10m | US$695k | -US$182m |
| Sep 30 2021 | n/a | n/a | -US$251m |
| Jun 30 2021 | n/a | n/a | -US$239m |
| Mar 31 2021 | n/a | n/a | -US$229m |
| Dec 31 2020 | US$8m | US$675k | -US$316m |
| Sep 30 2020 | n/a | n/a | -US$243m |
| Jun 30 2020 | n/a | n/a | -US$227m |
| Mar 31 2020 | n/a | n/a | -US$207m |
| Dec 31 2019 | US$11m | US$600k | -US$185m |
| Sep 30 2019 | n/a | n/a | -US$154m |
| Jun 30 2019 | n/a | n/a | -US$147m |
| Mar 31 2019 | n/a | n/a | -US$240m |
| Dec 31 2018 | US$13m | US$362k | -US$212m |
Compensation vs Market: David's total compensation ($USD14.06M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Chang (63 yo)
5.9yrs
Tenure
US$14,061,848
Compensation
Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc since June 2018. He served as Chief Medical Officer and Executive Vice President of Rese...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 6.5yrs | US$9.36m | 3.13% $ 14.7m | |
| Co-Founder | 5.9yrs | US$14.06m | 3.06% $ 14.4m | |
| Co-Founder & Director | no data | US$684.49k | 0.18% $ 836.5k | |
| Executive VP & Chief Technical Officer | 1.1yrs | US$5.80m | 0.16% $ 732.7k | |
| Executive VP of Research & Development and Chief Medical Officer | 1.3yrs | US$8.13m | 0.022% $ 105.7k | |
| Executive VP & CFO | less than a year | no data | 0.00011% $ 518.3 | |
| Senior VP | less than a year | no data | 0% $ 0 | |
| Chief People Officer | 2yrs | no data | no data | |
| Executive VP | 1.3yrs | no data | no data | |
| Senior Vice President of Finance | no data | no data | 0.052% $ 245.3k | |
| Secretary | no data | no data | no data |
1.3yrs
Average Tenure
58yo
Average Age
Experienced Management: ALLO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 6.5yrs | US$9.36m | 3.13% $ 14.7m | |
| Co-Founder | 5.9yrs | US$14.06m | 3.06% $ 14.4m | |
| Co-Founder & Director | 6.5yrs | US$684.49k | 0.18% $ 836.5k | |
| Lead Independent Director | 6.1yrs | no data | no data | |
| Independent Director | 6.1yrs | US$585.00k | 0.13% $ 632.5k | |
| Independent Director | 6.1yrs | US$510.00k | 0.15% $ 705.3k | |
| Independent Director | 6.1yrs | no data | no data | |
| Independent Director | 5.7yrs | US$495.00k | 0.015% $ 69.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | no data | no data |
6.1yrs
Average Tenure
64yo
Average Age
Experienced Board: ALLO's board of directors are considered experienced (6.1 years average tenure).